SINGLE STUDY DATA UP TO 144 WEEKS
|
|
- Bruno James
- 5 years ago
- Views:
Transcription
1 SINGLE STUDY DATA UP TO 144 WEEKS Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14a(3) Date of preparation: August 2017 Prescribing information is available at the end of this presentation
2 KEY STUDIES ATRIPLA SINGLE Treatment-naïve patients TRIUMEQ QD vs Atripla QD (N=833) SUPERIOR EFFICACY vs Atripla at weeks 48 (primary endpoint), 96 and 144 1,2 BOOSTED Pls FLAMINGO ARIA Treatment-naïve patients DTG + 2 NRTIs QD vs DRV/r + 2 NRTIs QD (N=484) Treatment-naïve women TRIUMEQ QD vs ATV/r + TDF/FTC QD (N=495) SUPERIOR EFFICACY vs darunavir/r at weeks 48 (primary endpoint) and 96 3,4 SUPERIOR EFFICACY vs atazanavir/r at week 48 (primary endpoint) 5 SPRING-2 Treatment-naïve patients DTG + 2 NRTIs QD vs RAL + 2 NRTIs BID (N=822) NON-INFERIOR EFFICACY vs raltegravir at weeks 48 (primary endpoint) and 96 6,7 INIs SAILING Treatment-experienced, INI-naïve patients DTG QD + BR* vs RAL BID + BR* (N=719) SUPERIOR EFFICACY vs raltegravir at week 48 (primary endpoint) 8 Continuing ART STRIIVING Treatment-experienced, stable-switch patients TRIUMEQ QD vs continuing ARV regimen (N=551) NON-INFERIOR EFFICACY up to weeks 24 (primary endpoint) and 48 9,10 Heavily Treatment Experienced VIKING-3 Heavily treatment experienced patients with RAL and/or EVG resistant HIV-1 DTG 50mg BD + OBR** (N=183)-single-arm study SUSTAINED EFFICACY up to weeks 24 (primary endpoint) and DTG 50mg + ABC 600mg/3TC 300mg were used. Bioequivalence has been demonstrated. 12 * BR - background regimen ** OBR - optimised background regimen 1. Walmsley S et al. N Engl J Med. 2013;369(19): Walmsley S et al. J Acquir Immune Defic Syndr. 2015;70: Clotet B et al. Lancet. 2014;383(9936): Molina J-M et al. Lancet HIV.2015;2(4):e127-e Orrell C et al. Presented at 21st International AIDS Conference, 18th-22nd July, 2016; Durban, South Africa. Abstract THAB0205LB. 6. Raffi F et al. Lancet Infect Dis. 2013;13: Raffi F et al. Lancet. 2013; 381: Cahn P et al. Lancet. 2013; 382: Trottier B et al. Presented at 55th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17th-21st September, 2015; San Diego, CA. LB Lake JE et al. Presented at 21st International AIDS Conference, 18th-22nd July, 2016; Durban, South Africa. Abstract THAB Castagna A et al. J Infect Dis. 2014; 210: Triumeq SmPC January 2017.
3 SINGLE STUDY DESIGN Treatment-naïve, HIV-1 positive HLA-B*5701 negative HIV-1 RNA 1000 c/ml Creatinine clearance >50 ml/min Stratified by baseline viral load and CD4 cell count DTG 50 mg QD plus ABC/3TC FDC plus EFV/TDF/FTC placebo (n=414) EFV/TDF/FTC QD plus DTG + ABC/3TC FDC placebo (n=419) DTG 50 mg QD plus ABC/3TC open label EFV/TDF/FTC QD open label Week 48 Week 96 Week 144 Primary endpoint: Proportion with HIV-1 RNA <50 c/ml at Week 48, FDA snapshot analysis (-10% non-inferiority margin with pre-specified tests for superiority) Adapted from Walmsley S, et al. N Engl J Med 2013; 369: ; Pappa K, et al. Oral presentation at: 54th ICAAC 2014; H-647a
4 BASELINE CHARACTERISTICS Characteristic DTG 50 mg +ABC/3TC QD (n=414) EFV/TDF/FTC QD (n=419) Median age, years (range) 36 (18-68) 35 (18-85) Female, n (%) 67 (16) 63 (15) African American/African Heritage, n (%) 98 (24) 99 (24) CDC class C, n (%) 18 (4) 17 (4) Baseline HIV-1 RNA Median (log10 c/ml) >100,000 c/ml, n (%) 134 (32) 131 (31) Median CD4 cell count, cells/mm <200, % to <350, % to <500, % , % Adapted from Walmsley S, et al. N Engl J Med 2013; 369: and supplementary appendix
5 Proportion with HIV-1 RNA <50 copies/ml DTG + ABC/3TC DEMONSTRATED STATISTICALLY SUPERIOR EFFICACY VS EFV/TDF/FTC AT 48, 96 AND 144 WEEKS DTG + ABC/3TC demonstrated rapid suppression of viral load vs EFV/TDF/FTC (28 days vs 84 days, respectively; P<0.0001) Favours EFV/TDF/FTC W48 W96 W144-5% 95% CI for difference 0 DTG 50 mg + ABC/3TC FDC QD (n=414) 88% 81% Favours DTG + ABC/3TC 2.5% 2.3% 2% 7.4% 8.0% 8.3% 12.3% 13.8% 14.6% p=0.003 p=0.006 p= % 72% Week -10% non-inferiority margin with pre-specified tests for superiority ATRIPLA (EFV/TDF/FTC) is not licensed in the UK or Ireland for initial use in treatment-naive patients. Adapted from Walmsley S, et al. N Engl J Med 2013; 369: ; Walmsley S, et al. J Acquir Immune Defic Syndr 2015; 70(5): % EFV/TDF/FTC QD (n=419) DTG + ABC/3TC: 71% EFV/TDF/FTC: 63%
6 DTG WAS EFFECTIVE VS ATRIPLA REGARDLESS OF BASELINE VIRAL LOAD Percent With HIV-1 RNA <50 c/ml Week ,000 >100,000 Baseline plasma HIV-1 RNA, c/ml DTG 50 mg + ABC/3TC FDC QD (n=414) EFV/TDF/FTC QD (n=419) 32% of treatmentnaïve patients had a baseline viral load >100,000 copies/ml P=0.831; test for homogeneity; P value confirms that there is no evidence of heterogeneity in treatment difference across the baseline stratification factors Adapted from: Abstract H-556b Walmsley S, et al. N Engl J Med 2013; 369: and supplementary appendix; Walmsley S, et al. J Acquir Immune Defic Syndr 2015; 70 (5):
7 DTG HAD STATISTICALLY SUPERIOR CD4 + T-CELL INCREASES VS ATRIPLA UP TO 144 WEEKS Adjusted mean change from baseline CD4+ cell count (cells/mm 3 ) DTG + ABC/3TC 267 cells/mm 3 EFV/TDF/FTC 208 cells/mm 3 Week 48 difference in response (95% CI): 59% [33%, 84%]; P<0.001 DTG 50 mg + ABC/3TC FDC QD (n=414) EFV/TDF/FTC QD (n=419) Week DTG + ABC/3TC 325 cells/mm 3 EFV/TDF/FTC 281 cells/mm 3 Week 96 difference in response (95% CI): 44% [14%, 74%]; P=0.004 DTG + ABC/3TC 379 cells/mm 3 EFV/TDF/FTC 332 cells/mm 3 Week 144 difference in response (95% CI): 47% [16%, 78%]; P=0.003 Adapted from: Walmsley S, et al. 52nd ICAAC Sept Abstract H-556b; Walmsley S, et al. N Engl J Med 2013;369: ; Walmsley S, et al. Poster presented at: 21st CROI 2014;Poster 543; Pappa K, et al. Oral presentation at: 54th ICAAC 2014;H-647a
8 FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS UP TO 144 WEEKS WITH DTG VS ATRIPLA Discontinuations due to AEs were 4% for DTG + ABC/3TC vs 14% for EFV/TDF/FTC at Week 144 Proportion (%) of patients with AE leading to discontinuation DTG 50 mg + ABC/3TC FDC QD (n=414) EFV/TDF/FTC QD (n=419) Week 48 Week 96 Week 144 Adapted from Walmsley S, et al. N Engl J Med 2013; 369: ; Walmsley S, et al. Poster presented at: 21st CROI Poster 543; Pappa K, et al. Oral presentation at: 54th ICAAC 2014 ; H-647a
9 DTG WAS GENERALLY BETTER TOLERATED VS ATRIPLA UP TO 144 WEEKS WITH FEWER DISCONTINUATIONS The incidence of psychiatric or nervous system disorders leading to withdrawal up to 144 weeks was <1% each for DTG + ABC/3TC and 6%, 4% respectively for EFV/TDF/FTC Proportion (%) of patients with AE leading to withdrawal Common AEs leading to withdrawal by system organ class ( 2% in either arm) 6 <1 <1 <1 Psychiatric disorders Nervous system disorders Skin and subcutaneous tissue disorders 4 2 DTG 50 mg + ABC/3TC FDC QD (n=414) EFV/TDF/FTC QD (n=419) General disorders and administration site conditions 2 Gastrointestinal disorders Adapted from Pappa K, et al. Oral presentation at: 54th ICAAC 2014 ; H-647a
10 CHANGE FROM BASELINE TO 144 WEEKS IN RENAL PARAMETERS Mean change from baseline (SD) in serum creatinine, µmol/l No. of patients DTG 50 mg + ABC/3TC QD EFV/TDF/FTC QD 25 EFV/TDF/FTC QD BL Week DTG + ABC/3TC QD EFV/TDF/FTC QD Parameter Week 48 Week 96 Week 144 Week 48 Week 96 Week 144 Urine albumin/creatinine ratio Mean change (SD) 10.2 (9.02) 12.5 (9.98) 12.2 (10.51) -0.7 (8.34) 1.3 (8.70) 1.6 (9.52) Baseline µmol/l: DTG: 75.0 versus EFV/TDF/FTC: 74.6 DTG 50 mg + ABC/3TC QD Conversion rate: 1 µmol/l = 0.011mg/dL Adapted from Pappa K, et al. ICAAC Abstract H-647a
11 DTG HAS DEMONSTRATED A HIGH BARRIER TO RESISTANCE TO DATE No INI or NRTI resistance seen with DTG up to 144 weeks DTG 50 mg + ABC/3TC FDC QD (n=414) EFV/TDF/FTC QD (n=419) Week 48 Week 96 Week 144 Week 48 Week 96 Week 144 INI-resistant major substitution 0 0 * 0 * N/A N/A N/A NRTI major mutations ** 1 1 NNRTI major mutations N/A N/A N/A *E157Q/P polymorphism detected in 1 patient with no significant change in INI phenotypic susceptibility ** Treatment emergent NRTI mutations detected: K65K/R Treatment-emergent NNRTI mutations detected: K101E (n=1), K103K/N (n=1), G190G/A (n=1) and K103N+G190G/A (n=1) Treatment emergent NRTI mutations detected: K65R Treatment-emergent NNRTI mutations detected: K101E (n=1); K103N (n=1); K103K/N (n=2), G190A (n=1) and K103N+G190G/A (n=1) Treatment-emergent NNRTI mutations detected: K101E (n=1); K103N (n=2); K103K/N (n=2), G190A (n=2) Pappa K, et al. Oral presentation at: 54th ICAAC 2014;H-647a; Walmsley S, et al. N Engl J Med 2013;369: and supplementary appendix; Walmsley S, et al. Poster presented at: 21st CROI Poster 543
12 DTG IN TREATMENT-NAIVE PATIENTS SINGLE STUDY 144 WEEK DATA: SUMMARY DTG + ABC/3TC had statistically superior efficacy vs EFV/TDF/FTC 88% vs 81% were undetectable at 48 weeks (P=0.003) 80% vs 72% remained subsequently undetectable at 96 weeks (P=0.006) 71% vs 63%remained subsequently undetectable at 144 weeks (P=0.010) DTG + ABC/3TC is effective regardless of baseline viral load 83% of treatment-naive patients with HIV-1 RNA > 100,000 copies/ml remained undetectable at 48 weeks DTG + ABC/3TC was still as effective as EFV/TDF/FTC in patients with high baseline viral loads at 96 weeks 69% of treatment-naive patients with HIV-1 RNA > 100,000 copied/ml remained undetectable at 144 weeks DTG + ABC/3TC was generally better tolerated vs EFV/TDF/FTC with fewer discontinuations 2% vs 10% discontinuation due to AEs at 48 weeks 3% vs 11% discontinued due to AEs at 96 weeks 4% vs 14% discontinuation due to AEs at 144 weeks No INI or NRTI resistance up to 144 weeks with DTG + ABC/3TC TIVICAY Summary of Product Characteristics, July 2017; Walmsley S, et al. N Engl J Med 2013; 369: ; Walmsley S, et al. Poster presented at: 21st CROI Poster 543; Pappa K, et al. Oral presentation at: 54th ICAAC 2014; H-647a
13 TIVICAY (DOLUTEGRAVIR) LICENSED INDICATION TIVICAY is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age Population Patients without documented or clinically suspected resistance to the integrase class Patients without documented or clinically suspected resistance to the integrase class, when co-administered with some medicines e.g. efavirenz, nevirapine, tipranavir/ritonavir or rifampicin Patients with resistance to the integrase class (documented or clinically suspected) Recommended dose 50 mg once daily 50 mg twice daily 50 mg twice daily In the presence of documented resistance including Q secondary mutations from G140A/C/S, E138A/K/T, L74I, an increased dose may be considered for patients with limited treatment options (less than 2 active agents) due to advanced multi class resistance Adolescents aged 12 and above and weighing at least 40 kg and without documented or suspected resistance to the integrase class Children aged 6-<12 and weighing at least 15 kg and without documented or suspected resistance to the integrase class 100mg twice daily 50 mg once daily Dose according to bodyweight 10mg and 25mg tablets available Tivicay Summary of Product Characteristics, July 2017
14 SUPPLEMENTARY SAFETY INFORMATION
15 DTG HAD A LOWER IMPACT ON LIVER CHEMISTRY THAN ATRIPLA AT WEEK 48 Parameter/Criteria, (%) at Week 48 1 DTG 50 mg + ABC/3TC FDC QD (n=414) EFV/TDF/FTC QD (n=419) Subjects meeting 1 FDA stopping criteria 10 ( 2) 39 ( 9) ALT 20xULN 0 0 ALT 5xULN 1 (<1) 2 (<1) ALT 3xULN 5 ( 1) 15 ( 4) Total bilirubin >1.5xULN 3 (<1) 2 (<1) Alkaline phosphatase >1.5xULN 1 (<1) 19 ( 5) ALT and/or AST >3xULN and total bilirubin >1.5xULN 0 0 ALT, alanine amino transferase; AST, aspartate amino transferase; ULN, upper limit of normal Walmsley S, et al. 52nd ICAAC Sept Oral H-556b
16 DTG HAD A LOWER IMPACT ON LIVER CHEMISTRY THAN ATRIPLA AT WEEK 144 Grade 2 or higher ALT elevations were observed more commonly in the EFV/TDF/FTC arm than in the DTG + ABC/3TC arm at Week 144 Proportion (%) of patients with Grade 2 or higher ALT elevations DTG 50 mg + ABC/3TC FDC QD (n=414) EFV/TDF/FTC QD (n=419) Adapted from Walmsley S, et al. Poster presented at: 21st CROI Poster 543; Walmsley S, et al. JAIDS 2015;70(5):
17 ABBREVIATIONS 3TC, lamivudine ABC, abacavir AE, adverse event ALT, alanine amino transferase AST, aspartate amino transferase BID, twice daily c/ml, copies/ml CDC, Centers for Disease Control CI, confidence interval Cr, creatinine DRV, darunavir DRV/r, darunavir/ritonavir DTG, dolutegravir EFV, efavirenz FDA, Food and Drug Administration FDC, fixed dose combination FTC, emtricitabine HIV, human immunodeficiency virus HSR, hypersensitivity reaction INI, integrase inhibitor NRTI, nucleoside reverse transcriptase inhibitor NNRTI, non-nucleoside reverse transcriptase inhibitor PK, pharmacokinetic QD, once daily RAL, raltegravir RNA, ribonucleic acid TDF, tenofovir disoproxil fumarate ULN, upper limit of normal
18 PRESCRIBING INFORMATION TIVICAY DOLUTEGRAVIR 10MG, 25MG & 50MG TABLETS SEE SUMMARY OF PRODUCT CHARACTERISTICS BEFORE PRESCRIBING Indication: HIV in >6 years and >15kg as part of combination therapy. Dosing: Adults & adolescents >40kg: 50mg once daily with or without food if no proven/ suspected integrase resistance. Children 6 to <12 years: dose according to bodyweight: 15-<20kg: 20mg once daily (2x10mg); 20- <30kg: 25mg once daily; 30-<40kg: 35mg once daily (1 x 25mg + 1 x 10mg); When co-administered with efavirenz, nevirapine, tipranavir/ritonavir, etravirine (without boosted PI), carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John s Wort or rifampicin, Tivicay 50mg twice daily in adults/adolescents or the weight-based once daily dose twice daily in paediatric patients. Adults with proven/ suspected integrase resistance: 50mg twice daily preferably with food. Limited data in paediatric patients with proven/suspected integrase resistance. Elderly: Limited data in 65+ yrs. Caution in severe hepatic impairment. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Risk of hypersensitivity reactions. Discontinue dolutegravir and other suspect agents immediately if suspected. Risks of osteonecrosis, immune reactivation syndrome. Monitor LFTs in Hepatitis B/C co-infection and ensure effective Hepatitis B therapy. Caution with metformin: monitor renal function and consider metformin dose adjustment. Use with etravirine requires boosted PI or increased dose of dolutegravir. Use with Mg/Al-containing antacids, calcium, multivitamins or iron requires dosage separation. Pregnancy/ lactation: Not recommended. Avoid breast-feeding. Side effects: See SmPC for full details. Headache, GI disturbance, insomnia, abnormal dreams, depression, dizziness, rash, pruritus, fatigue, elevations of ALT, AST and CPK, arthralgia, myalgia, hypersensitivity, suicidal ideation or suicide attempt. Basic NHS costs: for 30 x 50mg tablets EU/1/13/892/ for 30 x 10mg tablets (EU/1/13/892/003) for 30 x 25mg tablets (EU/1/13/892/005). MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT. Trade marks are owned by or licensed to the ViiV Healthcare group of companies. Date of approval: July Zinc code: UK/DLG/0055/13(11) Adverse events should be reported. For the UK, reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: , medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on POM S1A
19 PRESCRIBING INFORMATION TRIUMEQ (DOLUTEGRAVIR 50MG/ABACAVIR 600MG/LAMIVUDINE 300MG TABLETS) (SEE SUMMARY OF PRODUCT CHARACTERISTICS BEFORE PRESCRIBING) Indication: HIV in over 12 years and > 40kg. Screen for HLA-B*5701 prior to use. Do not use if HLA-B*5701 positive. Dose: one tablet once daily with or without food. Elderly: Limited data in 65+ yrs. Creatinine clearance <50ml/min or moderate/severe hepatic impairment: Not recommended. Monitor closely in mild hepatic impairment. Contraindications: Hypersensitivity to any ingredient. Co-administration with dofetilide. Warnings/precautions: Both abacavir and dolutegravir are associated with risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Triumeq without delay if HSR suspected. Never reintroduce any dolutegravir- or abacavir-containing product after suspected HSR. Risks of immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C co-infection. Inconclusive data on relationship between abacavir and MI; minimise all modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Not recommended if dolutegravir required b.d. (with etravirine [without boosted PI], efavirenz, nevirapine, rifampicin, boosted tipranavir, carbamazepine, oxcarbazepine, phenytoin, phenobarbital and St John s Wort). Use with cladribine not recommended. Use with Mg/Alcontaining antacids, calcium, multivitamins or iron requires dosage separation. Caution with metformin: monitor renal function and consider metformin dose adjustment. Pregnancy/lactation: Not recommended. Avoid breast-feeding. Side effects: See SPC for details. Headache, insomnia, sleep/dream disorders, GI disturbance, fatigue, hypersensitivity, anorexia, depression, dizziness, somnolence, lethargy, malaise, cough, nasal symptoms, rash, pruritus, alopecia, arthralgia, myalgia, asthenia, fever, elevations of ALT, AST and CPK, blood dyscrasias, suicidal ideation or suicide attempt, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis. Basic NHS costs: 30 tablets: EU/1/14/940/001. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT. POM S1A Trade marks are owned by or licensed to the ViiV Healthcare group of companies. Date of approval: July 2017 Zinc code: UK/TRIM/0037/14(8) Adverse events should be reported. For the UK, reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: , medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on
20 PRESCRIBING INFORMATION KIVEXA (ABACAVIR 600MG/LAMIVUDINE 300MG TABLETS) (SEE SUMMARY OF PRODUCT CHARACTERISTICS BEFORE PRESCRIBING) Indications: HIV in adults, adolescents and children weighing at least 25 kg as part of combination therapy. Screen for HLA-B*5701 prior to use. Dose: one tablet daily with or without food. Elderly: No pharmacokinetic data in 65+ yrs. Renal impairment: Creatinine clearance <50ml/min: not recommended. Hepatic impairment: not recommended in moderate or severe hepatic impairment. Monitor closely in mild hepatic impairment. Contraindications: Hypersensitivity to any ingredient. Warnings/precautions: Risk of hypersensitivity reactions (HSR). Do not initiate in HLA-B*5701+ or previous suspected abacavir HSR. Stop Kivexa without delay if HSR suspected. Never reintroduce any abacavir-containing product after suspected HSR. Risks of virological failure, immune reactivation syndrome, osteonecrosis, increased weight, lipids, glucose. Monitor LFTs in Hepatitis B/C coinfection. Inconclusive data on relationship between abacavir and MI; minimise modifiable CV risk factors (e.g. smoking, hypertension, hyperlipidaemia). Use with cladribine, emtricitabine or high doses of cotrimoxazole not recommended. Pregnancy/lactation: Not recommended. Avoid breast-feeding. Side effects: See SPC for full details. Hypersensitivity, GI disturbance, headache, anorexia, insomnia, rash, fever, lethargy, fatigue, malaise, arthralgia, muscle disorders, nasal symptoms, cough, alopecia, blood dyscrasias, rhabdomyolysis, lactic acidosis, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Basic NHS costs: 30 tablets: EU/1/04/298/002. MA holder: ViiV Healthcare UK Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS. Further information is available from Customer Contact Centre, GlaxoSmithKline UK Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT. POM S1A Trade marks are owned by or licensed to the ViiV Healthcare group of companies. Date of approval: July 2017 Zinc code: UK/ABC3TC/0008/13(10) Adverse events should be reported. For the UK, reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on Adverse events should be reported. For Ireland, adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: , medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on
SINGLE STUDY DATA UP TO 144 WEEKS
SINGLE STUDY DATA UP TO 144 WEEKS Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14a(2) Date of preparation: February 2017 Prescribing information is available at the
More informationFLAMINGO 96-WEEK PRESENTATION DATA
FLAMINGO 96-WEEK PRESENTATION DATA Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14j(4) Date of preparation: August 2017 Prescribing information is available at the
More informationFLAMINGO 96-WEEK PRESENTATION DATA
FLAMINGO 96-WEEK PRESENTATION DATA Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects UK/DLG/0083/14j(3) Date of preparation: February 2017 Prescribing information is available at the
More informationTRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA
TRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA *In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3tc 300 mg were used. Bioequivalence has been demonstrated. DTG, dolutegravir; ABC, abacavir; 3TC, lamivudine
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationGlaxoSmithKline, London, United Kingdom; 11 ViiV Healthcare, London, United Kingdom
Switching to Dolutegravir /Abacavir/Lamivudine Fixed Dose Combination ( FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks J Lake, 1 B Trottier, 2 J Garcia-Diaz, 3 H Edelstein,
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationIvy Song, 1 Kimberly Adkison, 2 Mark Lovern 3, Joannellyn Chiu 3, Jenny Huang 1, Cindy Vavro 1, Mounir Ait-Khaled 1, Brian Wynne 1 and Sherene Min 1
Pharmacokinetic-Pharmacodynamic Modeling & Simulation of the Virologic Response of Dolutegravir in HIV-Infected Patients with Integrase Inhibitor Resistant Virus Ivy Song, 1 Kimberly Adkison, 2 Mark Lovern
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationPrescribing Information can be found at the end of the presentation
Switching to Dolutegravir /Abacavir/Lamivudine Fixed Dose Combination ( FDC) from a PI, INI or NNRTI Based Regimen Maintains HIV Suppression at 48 Weeks Prescribing Information can be found at the end
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationIAC Analyst Presentation
IAC Analyst Presentation David Redfern Chairman, ViiV Healthcare Chief Strategy Officer, GSK July 27, 2012 1 ViiV Healthcare Dr Dominique Limet CEO, ViiV Healthcare July 27, 2012 2 Equity split of 85%
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationRALTEGRAVIR. October Produced by the London New Drugs Group on behalf of the HIV Drugs and Treatment sub-group of the London HIV Consortium
Page 1 Produced by the London New Drugs Group on behalf of the HIV Drugs and Treatment sub-group of the London HIV Consortium RALTEGRAVIR Contents Summary 1 Background 3 Interactions 3 Clinical efficacy
More informationH I V. CLUB s News News News News News News News News News News News News News News News News News News
Issue N o 34 H I V TRAINEES CLUB s News News News News News News News News News News News News News News News News News News Editorial Welcome to the current edition of the HIV Trainees Club Newsletter.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for REZOLSTA This is a summary of the risk management plan (RMP) for REZOLSTA. The RMP details important risks of REZOLSTA,
More informationIntroduction. Cahn et al. Andean Pacific HIV Clinical Forum 2017; Santiago, Chile. Abstract 2.
Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed Dose Combination (FDC) Compared With Ritonavir- Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN Summary of Risk Management Plan for PREZISTA (Darunavir [TMC114]) This is a summary of the risk management plan (RMP) for PREZISTA. The RMP details important
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationART: The New, The Old and The Ugly
ART: The New, The Old and The Ugly Our Current ARVS The Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTIs) Abacavir Emtricitabine Lamivudine Stavudine Tenofovir Zidovudine The Non-Nucleoside
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationPurpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation
ANDREW LEE Purpose Methods Demographics of patients in the study Outcome Efficacy Adverse Event Limitation Dolutegravir Integrase inhibitor Plasma half life 14hours Tivicay FDA (US)- 13 August 2013 50mg
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationDolutegravir Attributes
Dolutegravir (; S/GSK1349572) in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in Antiretroviral Naïve Adults: 96 Week Results from SPRING 1 (ING112276) Hans Juergen Stellbrink, 1
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all ages) NHS England Reference: B06/P/a
Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all ages) NHS England Reference: B06/P/a 1 2 Clinical Commissioning Policy: Dolutegravir for treatment of HIV-1 infection (all
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationImportant new concerns or changes to the current ones will be included in updates of Symtuza's RMP.
Summary of Risk Management Plan for Symtuza (D/C/F/TAF) This is a summary of the risk management plan (RMP) for Symtuza. The RMP details important risks of Symtuza, how these risks can be minimised, and
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationABACAVIR HYPERSENSITIVITY REACTION
ABACAVIR HYPERSENSITIVITY REACTION Abacavir is a component of Ziagen, Trizivir, Kivexa and Triumeq Version 2.0, March 2016 In the EU, this medicinal product (Triumeq) is subject to additional monitoring
More informationPrima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi
6 th INFECtivology TOday Paestum 15-16 -17 maggio 2014 Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi Istituto Nazionale per le Malattie
More informationABACAVIR HYPERSENSITIVITY REACTION
IE/HIV/0008/16; August 2016 Important Risk Minimisation Information for Healthcare Professionals Please refer to the Summary of Product Characteristics before prescribing ABACAVIR HYPERSENSITIVITY REACTION
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationREVIEW No Assessment of safety a. Have all relevant studies on safety been included Yes X No (if no, please provide reference and information)
Expert peer review on application for addition of fixed dose combination formulations of antiretroviral medications in the EML (Adults) REVIEW No. 2 Abacavir + lamivudine (ABC+ 3TC) Tablet (dispersible):
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationDTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone
DTG Versus LPV/r in Second Line (DAWNING): Outcomes by WHO- Recommended NRTI Backbone Aboud M, 1 Brites C, 2 Lu H, 3 Supparatpinyo K, 4 Hercilla L, 5 Sievers J, 1 Nascimento MC, 1 Hopking J, 6 Underwood
More informationProvides New Treatment Option for Stable, Virologically Suppressed Adults Living with HIV-1
MEDIA CONTACT: Rebecca Genin +1 215-620-8721 Rgenin1@its.jnj.com Kristina Chang +1 201-213-4115 Kchang12@its.jnj.com Katie Buckley +44 7971 956 179 kbuckle8@its.jnj.com INVESTOR RELATIONS: Lesley Fishman
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationCL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3
Durable Efficacy and Limited Integrase Resistance Evolution in Subjects Receiving Dolutegravir After Failing Prior Integrase Inhibitor (INI) Regimens: Week 48 Results from VIKING-3 CL Vavro, 1 J Huang,
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 May 2014 TIVICAY 50 mg, film-coated tablet Bottle of 30 (CIP: 34009 277 146 3 4). Applicant: VIIV HEALTHCARE SAS
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More informationHigher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
DOI: 10.1111/hiv.12468 ORIGINAL RESEARCH Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients C Hoffmann, 1,2 T Welz, 3 M Sabranski, 1 M Kolb,
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationDisclosures. Update on HIV Drug Therapy: A Case based Discussion. Case # 1: Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv
Disclosures Update on HIV Drug Therapy: A Case based Discussion Dr. Grant has received grant support from BMS, Gilead, Janssen, and Viiv Philip Grant Assistant Professor Division of Infectious Diseases
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More information43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) A Cutrell, J Hernandez, M Edwards, J Fleming, W Powell, T Scott
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster H-2013 Clinical Risk Factors for Hypersensitivity Reactions to Abacavir: Retrospective Analysis of Over 8,000 Subjects
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationJuluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW
Juluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW Introduction Brand name: Juluca Generic name: Dolutegravir, rilpivirine Pharmacological class: HIV-1 integrase strand transfer inhibitor (INSTI)
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationResistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Viruses 2014, 6, 2858-2879; doi:10.3390/v6072858 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationAntiviral Therapy 2015; 20: (doi: /IMP2878)
Antiviral Therapy 2015; 20:343 348 (doi: 10.3851/IMP2878) Short communication Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week
More informationBHIVA antiretroviral treatment guidelines 2015
BHIVA antiretroviral treatment guidelines 2015 Duncan Churchill Brighton & Sussex University Hospitals NHS Trust Laura Waters Mortimer Market Centre, CNWL Duncan Churchill GENERAL POINTS & WHEN TO START
More information